Premium
Imidazolium salts as antifungal agents: strong antibiofilm activity against multidrug‐resistant Candida tropicalis isolates
Author(s) -
Bergamo V.Z.,
Donato R.K.,
Dalla Lana D.F.,
Donato K.J.Z.,
Ortega G.G.,
Schrekker H.S.,
Fuentefria A.M.
Publication year - 2015
Publication title -
letters in applied microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.698
H-Index - 110
eISSN - 1472-765X
pISSN - 0266-8254
DOI - 10.1111/lam.12338
Subject(s) - biofilm , candida tropicalis , microbiology and biotechnology , in vivo , multiple drug resistance , in vitro , biology , antifungal , chemistry , bacteria , drug resistance , biochemistry , genetics
The in vitro activity of the imidazolium salt C 16 MI mCl against planktonic and biofilm cells of multidrug‐resistant isolates of Candida tropicalis was evaluated, both in solution and applied on a commercial catheter surface. This was determined by inhibition and susceptibility assays of biofilm and planktonic cells. In both cases, C 16 MI mCl prevented in vitro biofilm formation of C. tropicalis strains, including multidrug‐resistant ones. Outstanding performances were observed, even at extremely low concentrations. Furthermore, this is the first report of the antifungal lock property of C 16 MI mCl, using a tracheal catheter as the test specimen to mimic a clinical in vivo condition. As such, C 16 MI mCl has been identified as a promising antimicotic pharmaceutical candidate for the treatment of candidiasis infections. Significance and Impact of the Study The imidazolium salt 1‐ n ‐hexadecyl‐3‐methylimidazolium chloride (C 16 MImCl) strongly prevents, in concentrations as low as 0·028 μ g ml −1 , the biofilm formation of multidrug‐resistant C andida tropicalis isolates, either in solution or applied on the surface of commercial catheters. This presents an effective antimicotic candidate and alternative for invasive clinical procedure toolset asepsis.